at least 26 days after EVD symptom onset and demonstrate a case in which a baby was not infected by breast milk from his EBOV-positive mother. However, it should be noted that the woman’s breast milk was never tested while she was breast-feeding baby 2.

The literature on EBOV in breast milk of EBOV-positive patients is extremely scarce (3). In a previous study from the 2000 Sudan EBOV outbreak in Gulu, Uganda, breast milk from a convalescent-phase patient was sampled 15 days after symptom onset and tested positive for EBOV by RT-PCR and virus culture (4). Another study conducted in Guinea during the current outbreak, reported a mother–baby pair in which EVD developed in the baby 14 days after symptom onset in the mother, but breast milk from the mother sampled 17 days after symptom onset was negative by EBOV RT-PCR (1).

It is unclear whether infectious virus or defective particles are being secreted in breast milk. Ct values were consistently lower in breast milk than in blood when tested concomitantly, but in this case, breast milk samples were not collected until day 6. Our findings suggest that breast milk is infected by EBOV at a later stage of the disease than blood but then follows the expected replication kinetics observed in venous blood.

Considering the high EVD death rate, until further evidence is found, we recommend that EBOV-positive women stop breast-feeding immediately and that breast-feeding not be resumed until 2 negative RT-PCR tests of the breast milk have been confirmed. This suggestion is in line with the World Health Organization recommendation for testing semen in male EVD survivors (5). The public health risk for EBOV to remain in breast milk for at least 26 days after EVD symptom onset and for breast milk to possibly be infectious after a patient has cleared the virus from the blood should also be acknowledged.

References


Address for correspondence: Helena Nordenstedt, Department of Public Health Sciences (IHCAR), Karolinska Institutet, SE-171 77 Stockholm, Sweden; email: helena.nordenstedt@ki.se

Chronic Infection of Domestic Cats with Feline Morbillivirus, United States

Claire R. Sharp, Sham Nambulli, Andrew S. Acciardo, Linda J. Rennick, J. Felix Drexler, Bertus K. Rima, Tracey Williams, W. Paul Duprex

Author affiliations: Tufts University Cummings School of Veterinary Medicine, North Grafton, Massachusetts, USA (C.R. Sharp); Boston University School of Medicine, Boston, Massachusetts, USA (S. Nambulli, A.S. Acciardo, L.J. Rennick, W.P. Duprex); University of Bonn Medical Centre, Bonn, Germany (J.F. Drexler); German Center for Infection Research, Bonn-Cologne, Germany (J.F. Drexler); The Queen’s University of Belfast School of Medicine, Dentistry, and Biomedical Sciences, Belfast, Northern Ireland (B.K. Rima); Zoetis LLC, Kalamazoo, Michigan, USA (T. Williams)

DOI: http://dx.doi.org/10.3201/eid2204.151921
To the Editor: Feline morbillivirus (FeMV) was first reported in Hong Kong, and mainland China in 2012 (1) and has been associated with tubulointerstitial nephritis, the histopathologic correlate of idiopathic chronic kidney disease (CKD); however, this association has not been proven by studies in FeMV-naive animals. In 2013, phylogenetically related strains were found in Japan, indicating broader geographic distribution in Asia (2). The lack of complete genome sequences for strains from other regions prevents assessment of the clinical relevance and genetic diversity of FeMV. Classical morbilliviruses, such as measles and canine distemper viruses, have a global distribution, suggesting that FeMV might be present elsewhere in the world (3). To confirm the presence of FeMV and assess its genetic diversity and infection patterns in the United States, we collected and analyzed urine samples from domestic cats.

We generated amplicons from 10 (3%) of 327 samples; 3 samples were from cats with CKD and 7 from cats without CKD. Sequencing results confirmed that these 493 bp amplicons correspond to unique strains of FeMV. FeMVUS1 is 97% similar in the L gene amplicon sequence to FeMV776U (1), whereas FeMVUS5 is only 85% identical, making it very different to all previously identified FeMVs. We used these sequences to develop a pan-US primer set, priFeMVUSpanL+ and priFeMVUSpanL-, to amplify a highly conserved region (460 bp) of the L gene of the US strains (online Technical Appendix Table 1, http://wwwnc.cdc.gov/EID/article/22/4/15-1921-Techapp.pdf). The results of these analyses demonstrated that FeMV is present outside of Asia.

In October 2013, we obtained the initial FeMVUS1-positive sample from a healthy 4-year-old male domestic short-hair cat (animal 0213). Approximately 15 months later, we obtained a follow-up urine sample from the still healthy cat, performed reverse transcription PCR (RT-PCR), and generated amplicons (online Technical Appendix Figure, panel A). Amplification and sequencing of the hemagglutinin (H) gene from the 2015 sample indicated that it was identical to that from the 2013 sample, suggesting that the cat was chronically infected. We developed a quantitative RT-PCR test by using L gene primers and a real-time probe (online Technical Appendix Table 2). Results indicated stable and comparable virus loads: 9.8 × 10^4 copies/mL in 2013 versus 7.8 × 10^4 copies/mL in 2015. This finding corroborates the view that cats can be chronically infected with FeMV and that the virus is persistently shed in urine.

We used primers to generate cDNA from clinical material and then determined the complete genome sequence of FeMVUS1 (GenBank accession no. KR014147) by using RT-PCR and rapid amplification of cDNA ends. The major morbillivirus surface antigen is the H glycoprotein, and we used pan-FeMV H gene primer sets to detect additional viruses (e.g., FeMVUS2) (online Technical Appendix Figure, panel B). An indirect immunofluorescence assay was developed to screen serum samples for FeMV-specific antibodies. Antibodies to FeMVUS1 were detected in fixed cells expressing FeMV H glycoprotein (positive up to 1:12,800 dilution), and antibodies to FeMVUS5 were detected in non-permeabilized cells (positive up to 1:6,400 dilution) (online Technical Appendix Figure 2). This result confirms that H

Figure. Phylogenetic analysis of feline morbillivirus (FeMV) whole genomes and hemagglutinin (H) genes collected from cats in the United States. A) Genomic sequence identity of FeMVUS1, compared with Asian strains, performed by using SSE V1.2 software (4) with a sliding window of 400 and a step size of 40 nt. B) Maximum-likelihood phylogeny of the translated H gene of FeMVs, the genus Morbillivirus, sensu strictu, and unclassified morbilli-related viruses was determined by using MEGA5 software (5) and applying the Whelan-and-Goldman substitution model and a complete deletion option. Numbers at nodes indicate support of grouping from 1,000 bootstrap replicates. Scale bar indicates substitutions per site.
glycoprotein–specific antibodies are present at high levels concurrent with the longitudinal detection of genomic RNA. A large-scale seroprevalence and cross-neutralization study is ongoing.

We used complete genome and H gene sequences in a comprehensive phylogenetic analysis. FeMVUS1 is closely related to viruses from Asia, highlighting the global distribution of FeMV (Figure, panel A). Compared with the sequence for the FeMV762U H gene, sequences for FeMVUS1 and FeMVUS5 were 98% and 81% similar, and the glycoproteins were 98% and 86% identical. The complete H gene of the most divergent US strain (FeMVUS5) clustered phylogenetically in a basal sister relationship with all other viruses from Asia and the United States (Figure, panel B), suggesting a long evolutionary association of FeMV in feline hosts.

Ecologic surveys continue to identify novel viruses that are homologous to known paramyxoviruses in many wildlife species, including bats and rodents (6). Investigating closely related viruses in domestic species is warranted, given the substantial number of animals that cohabit with humans. Switches from natural to unnatural host species can result in enhanced pathogenicity (e.g., receptor switching has caused feline panleukopenia virus to infect dogs as canine parvovirus) (7). Given the high degree of antigenic relatedness of morbilliviruses, understanding evolutionary origins and trajectories and conferring cross-protection through immunization are critical. Although no evidence for FeMV transmission to humans or other animals exists, the propensity for noncanonical use of signaling lymphocytic activation molecule 1 F1 (CD150) should be investigated because epizootic transmission of morbilliviruses can occur (8).

The detection of FeMV sequences in a clinically healthy animal after 15 months is a novel and surprising observation but is consistent with the known propensity for morbilliviruses to persist in vivo (9). All known morbilliviruses cause acute infections, and the typical long-term clinical manifestations occur in the central nervous system, not the urinary system (1). These observations should prompt additional research because the prevalence of CKD in cats is high and because CKD decreases the quality of life of affected animals and is the ultimate cause of death for approximately one third of cats (10).

Acknowledgments
We thank Florence Lee, Diane Welsh, Karen Greenwood, Graeme Bainbridge, Betsy Galvan, and Rik de Swart for helpful suggestions, critical reading of the manuscript, and technical support. We thank the Winn Foundation for previous support.

Funding for this study was provided by Boston University and Zoetis LLC.

References

Address for correspondence: W. Paul Duprex, Department of Microbiology, Boston University School of Medicine, 620 Albany St, Boston, MA 02118, USA; email: pduprex@bu.edu

Difficulties in Schistosomiasis Assessment, Corsica, France

Hélène Moné, Martha C. Holtfreter, Gabriel Mouahid, Joachim Richter

Author affiliations: University of Perpignan, Perpignan, France (H. Moné, G. Mouahid); Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany (M.C. Holtfreter, J. Richter)

DOI: http://dx.doi.org/10.3201/eid2204.160110

To the Editor: We would like to add some specification and clarification to the discussion regarding the diagnostics and case definitions for urinary schistosomiasis in travelers to Corsica, France (1–3). Evidence for a Schistosoma

762 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 4, April 2016